Hills Bank & Trust Co. Boosts Stake in Bristol-Myers Squibb Co (NYSE:BMY)

Share on StockTwits

Hills Bank & Trust Co. boosted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 16.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,537 shares of the biopharmaceutical company’s stock after purchasing an additional 3,235 shares during the quarter. Hills Bank & Trust Co.’s holdings in Bristol-Myers Squibb were worth $1,247,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in BMY. BlackRock Inc. raised its holdings in Bristol-Myers Squibb by 5.0% during the 4th quarter. BlackRock Inc. now owns 104,293,294 shares of the biopharmaceutical company’s stock valued at $6,391,093,000 after buying an additional 4,945,515 shares during the period. Geode Capital Management LLC raised its position in shares of Bristol-Myers Squibb by 4.4% during the fourth quarter. Geode Capital Management LLC now owns 18,583,469 shares of the biopharmaceutical company’s stock valued at $1,136,568,000 after buying an additional 777,929 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Bristol-Myers Squibb by 31.9% during the fourth quarter. Renaissance Technologies LLC now owns 14,302,900 shares of the biopharmaceutical company’s stock valued at $876,482,000 after buying an additional 3,456,300 shares during the last quarter. TIAA CREF Investment Management LLC raised its position in shares of Bristol-Myers Squibb by 30.8% during the fourth quarter. TIAA CREF Investment Management LLC now owns 10,932,722 shares of the biopharmaceutical company’s stock valued at $669,957,000 after buying an additional 2,573,967 shares during the last quarter. Finally, Orbis Allan Gray Ltd raised its position in shares of Bristol-Myers Squibb by 31.1% during the fourth quarter. Orbis Allan Gray Ltd now owns 6,901,670 shares of the biopharmaceutical company’s stock valued at $422,935,000 after buying an additional 1,635,666 shares during the last quarter. 71.39% of the stock is currently owned by institutional investors and hedge funds.

Shares of Bristol-Myers Squibb opened at $60.17 on Thursday, according to MarketBeat Ratings. Bristol-Myers Squibb Co has a one year low of $49.96 and a one year high of $70.05. The stock has a market capitalization of $96.70 billion, a PE ratio of 19.99, a PEG ratio of 1.49 and a beta of 1.02. The company has a quick ratio of 1.28, a current ratio of 1.40 and a debt-to-equity ratio of 0.46.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $0.14. The company had revenue of $5.70 billion during the quarter, compared to the consensus estimate of $5.48 billion. Bristol-Myers Squibb had a net margin of 1.74% and a return on equity of 42.58%. The company’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.74 EPS. research analysts forecast that Bristol-Myers Squibb Co will post 3.62 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 1st. Stockholders of record on Friday, July 6th were paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.66%. The ex-dividend date was Thursday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 53.16%.

A number of research analysts have recently commented on the stock. Jefferies Financial Group set a $58.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Sunday, July 15th. Atlantic Securities raised shares of Bristol-Myers Squibb from an “underweight” rating to a “neutral” rating and set a $57.00 target price on the stock in a research note on Wednesday. ValuEngine raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, July 14th. Bank of America decreased their price objective on shares of Bristol-Myers Squibb from $68.00 to $61.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 17th. Finally, Morgan Stanley cut shares of Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $54.08 to $58.00 in a research note on Tuesday, April 17th. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have given a buy rating to the company. Bristol-Myers Squibb has an average rating of “Hold” and an average price target of $63.11.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Further Reading: Should I follow buy, hold and sell recommendations?

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.